AGS15E
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Urothelial Cancer
Conditions
Metastatic Urothelial Cancer
Trial Timeline
Nov 14, 2013 โ Jul 8, 2019
NCT ID
NCT01963052About AGS15E
AGS15E is a phase 1 stage product being developed by Astellas Pharma for Metastatic Urothelial Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01963052. Target conditions include Metastatic Urothelial Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01963052 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Urothelial Cancer